Genprex, Inc. SEC filings GNPX
Genprex, Inc. has 491 filings in SEC EDGAR's recent list, going back to Dec 26, 2013. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 12, 2025 | — |
| CORRESP | Letter to the SEC | Dec 10, 2025 | — |
| EFFECT | Filing | Sep 16, 2025 | — |
| CORRESP | Letter to the SEC | Sep 12, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2025 | — |
| DRS | Filing | Sep 5, 2025 | — |
| RW | Form rw | Aug 5, 2025 | — |
| EFFECT | Filing | Jun 17, 2025 | — |
| CORRESP | Letter to the SEC | Jun 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2025 | — |
| DRS | Filing | Apr 24, 2025 | — |
| NT 10-K | Form nt 10-k | Apr 1, 2025 | Dec 31, 2024 |
| NT 10-Q | Form nt 10-q | Aug 15, 2023 | Jun 30, 2023 |
| EFFECT | Filing | Jun 9, 2023 | — |
| CORRESP | Letter to the SEC | Jun 7, 2023 | — |
| NT 10-Q | Form nt 10-q | May 16, 2023 | Mar 31, 2023 |
| UPLOAD | Letter from the SEC | Apr 27, 2023 | — |
| RW | Form rw | Oct 2, 2020 | — |
| EFFECT | Filing | Jul 17, 2020 | — |
| CORRESP | Letter to the SEC | Jul 15, 2020 | — |
| CORRESP | Letter to the SEC | Jul 1, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2020 | — |
| EFFECT | Filing | May 20, 2020 | — |
| CORRESP | Letter to the SEC | May 18, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2020 | — |
| D | Filing | Nov 22, 2019 | — |
| EFFECT | Filing | Oct 28, 2019 | — |
| CORRESP | Letter to the SEC | Oct 24, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2019 | — |
| CORRESP | Letter to the SEC | Oct 16, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2019 | — |
| CORRESP | Letter to the SEC | Oct 4, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2019 | — |
| NT 10-Q | Filing | May 16, 2019 | Mar 31, 2019 |
| EFFECT | Filing | Jul 26, 2018 | — |
| CORRESP | Letter to the SEC | Jul 26, 2018 | — |
| CORRESP | Letter to the SEC | Jul 13, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2018 | — |
| CORRESP | Letter to the SEC | Jun 15, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2018 | — |
| D | Filing | May 23, 2018 | — |
| NT 10-K | Filing | Apr 3, 2018 | Dec 31, 2017 |
| POS EX | Post-effective amend. no. 2 to form s-1 | Mar 29, 2018 | — |
| CERT | Filing | Mar 28, 2018 | — |
| EFFECT | Filing | Dec 29, 2017 | — |
| EFFECT | Filing | Oct 13, 2017 | — |
| 8-A12B | Form 8-a12b | Oct 13, 2017 | — |
| CORRESP | Letter to the SEC | Oct 12, 2017 | — |
| CORRESP | Letter to the SEC | Oct 12, 2017 | — |
| CORRESP | Letter to the SEC | Oct 10, 2017 | — |
| CORRESP | Letter to the SEC | Sep 26, 2017 | — |
| CORRESP | Letter to the SEC | Sep 22, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2017 | — |
| CORRESP | Letter to the SEC | Sep 15, 2017 | — |
| CORRESP | Letter to the SEC | Sep 8, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 1, 2017 | — |
| CORRESP | Letter to the SEC | Aug 18, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2017 | — |
| CORRESP | Letter to the SEC | Jul 20, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2017 | — |
| DRSLTR | Filing | Jun 5, 2017 | — |
| DRS | Filing | Jun 5, 2017 | — |
| D | Filing | Oct 4, 2016 | — |
| D | Filing | Mar 4, 2015 | — |
| D | Filing | Dec 30, 2013 | — |
| D | Filing | Dec 30, 2013 | — |
| D | Filing | Dec 26, 2013 | — |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1595248
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.